Last reviewed · How we verify

NCT05607303

Effect of Hormones on Frequency of Headache and Brain Structure and Function in Puberty

Active, enrolled Last updated 4 July 2025
What this trial tests

trial testing Clinical estrogen therapy in Headache in 140 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
14 December 2021
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorUniversity of Colorado, Denver
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment140
Start date14 December 2021
Primary completion30 June 2026
Estimated completion30 June 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 9 to 20, any sex, with Headache or Gender Identity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With a rising population of transgender adults and youth, there is a need for more research to meet the needs of this community. Transfemale (MTF) youth (male sex, female gender identity) who begin clinical Gender Affirming Hormone Therapy (GAHT) with estrogen may be at a higher risk for headache since estrogen has been linked to headache in cisgender females (female sex, female gender identity). This research hopes to learn more about headache in MTF youth.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Headache

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05607303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing